OS Therapies Inc
No SEC Form 4 filings for $OSTX in the last 30 days.
See all $OSTX insider activity →OS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.
OS Therapies Inc (OSTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2026, the stockholders of OS Therapies Incorporated (the “Company”) approved and adopted the amendment and
OS Therapies reported 71.2% 3-year survival for OST-HER2-treated patients vs. 45.8% in historical controls (p=0.002). The company received $3.15M in VAT refunds and anticipates $7.2M more. It plans to submit regulatory applications for OST-HER2 in Q4 2026. According to the company, OST-HER2 has received multiple designations from FDA and EMA.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OSTX (OS Therapies Inc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent OSTX coverage spans corporate actions, regulation and technology.
Regulatory alignment clears a key hurdle, likely boosting near‑term stock momentum ahead of the CMAA filing.
The new compensation plan may affect future dilution and executive incentives; director elections could influence governance.
The strong survival benefit validates OST-HER2's efficacy and supports upcoming BLA and regulatory submissions.
Potential dilution and cash inflow from the open market sale program.
Regulatory process milestone increases near-term visibility into how FDA will interpret efficacy controls and supports RMAT/Rolling Review decisions.
AlphAI scores every news story that mentions OSTX with an AI model for sentiment and relevance, and aggregates insider trades from OS Therapies Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
OS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.
2 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2026, the stockholders of OS Therapies Incorporated (the “Company”) approved and adopted the amendment and
1 min readOS Therapies reported 71.2% 3-year survival for OST-HER2-treated patients vs. 45.8% in historical controls (p=0.002). The company received $3.15M in VAT refunds and anticipates $7.2M more. It plans to submit regulatory applications for OST-HER2 in Q4 2026. According to the company, OST-HER2 has received multiple designations from FDA and EMA.
2 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares
1 min readOS Therapies (NYSE American: OSTX) said the U.S. FDA granted a Type C Statistical Methods meeting to review 2.5-year overall survival data for OST-HER2 from a Phase 2b trial in fully resected pulmonary metastatic osteosarcoma. Interim 3-year OS data are expected early Sept 2026. FDA comparator, RMAT, and Rolling Review decisions are expected after the mid-Sept 2026 meeting.
4 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Securities Purchase Agreement On August 10, 2026, OS Therapies Incorporated (the “Company”), together with its wholly owned subsidiaries, entered into a securities purchase agreement (the “Purchase Agreement”) with the purcha
4 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Leonite 2026 Secured Financing As previously disclosed, on June 30, 2026, OS Therapies Incorporated (the “Company”), together with its wholly owned subsidiaries, entered into a securities purchase agreement (the “Leonite SPA”
4 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement. On July 23, 2026, OS Therapies Incorporated (the “Company”) delivered to B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (together, the “Sales Agents”) written notice of termination of the At Market
2 min readOS Therapies Inc (OSTX) rose about 11% in morning trading after Roth/MKM initiated coverage with a Buy rating and $7.00 price target. The move lifted consensus to four Buys. The article cites upcoming U.S. FDA BLA submission by end-2026 and EMA submission by Sept. 30, 2026, plus recent convertible note funding.
4 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ea029686801ex10-1.htm SECURITIES PURCHASE AGREEMENT, DATED AS OF JUNE 30, 2026, AMONG OS THERAPIES INCORPORATED, OS ANIMAL HEALTH INC., OS THERAPIES UK LTD AND LEONITE FUND I, LP Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “ Agreem
4 min read
